...
首页> 外文期刊>Journal of Heterocyclic Chemistry: The International Journal of Heterocyclic Chemistry >Synthesis and Molecular Drug Efficacy of Indoline‐based Dihydroxy‐thiocarbamides: Inflammation Regulatory Property Unveiled over COX‐2 Inhibition, Molecular Docking, and Cytotoxicity Prospects
【24h】

Synthesis and Molecular Drug Efficacy of Indoline‐based Dihydroxy‐thiocarbamides: Inflammation Regulatory Property Unveiled over COX‐2 Inhibition, Molecular Docking, and Cytotoxicity Prospects

机译:吲哚基二羟基 - 硫代氨基甲酰胺的合成和分子药物疗效:在COX-2抑制,分子对接和细胞毒性前景上揭开炎症调节性能

获取原文
获取原文并翻译 | 示例
           

摘要

> In this study, substituted indoline‐based dihydroxy‐carbamides ( 5a–i ) were synthesized and evaluated as the cyclooxygenase‐2 (COX‐2) inhibitors to testify their inflammatory regulations through COX‐2 inhibition. Enzyme‐linked immunosorbent assay‐based competitive (COX‐2) inhibition ( in vitro ) followed by a molecular docking study ( in silico ) was executed to ensure the mode of interaction between 5a–i and COX‐2. Apart from COX‐2 inhibition studies, free‐radical scavenging ability (H 2 O 2 estimation method) and the human red blood cell membrane protection ( in vitro anti‐inflammatory) capability of the compounds 5a–i assessment were also evaluated. Excellent antimicrobial and anticancer activity exhibited by thiocarbamide substituted compounds ( 5a–d ) than carbamide ( 5e–i ). In molecular docking studies, the obtained binding affinity values of 5a–i indicated the therapeutic selectivity on COX‐2 (PDB ID: 1CX2) over COX‐1 (PDB ID: 1EQG). Established inhibitory constant ( ki ) values were found as low as in nanomolar/picomolar against COX‐2. Reliable COX‐2 inhibition of 78–92% and IC 50 0.002–1.28?μ M were obtained. Human red blood cell membrane was found to be effectively stabilized/protected by 5a–i up to 98%. Excellent antioxidant property (average radical scavenging 92%) and structure–activity relationship predictions confirmed the druggability potentials of 5a–i as effective, future anti‐inflammatory drugs. The cytotoxicity
机译:>在这项研究中,合成了取代的吲哚啉基二羟基氨基甲酸(5a–i)并将其评估为环氧合酶-2(COX-2)抑制剂,以通过COX-2抑制来证明其炎症调节作用。基于酶联免疫吸附试验的竞争性(COX-2)抑制(体外)随后进行了分子对接研究(硅),以确保5a–i和COX-2之间的相互作用模式。除了COX-2抑制研究外,还对化合物的自由基清除能力(H2O2估计方法)和人类红细胞膜保护能力(体外抗炎)进行了评估。硫代脲取代化合物(5a-d)比尿素(5e-i)具有优异的抗菌和抗癌活性。在分子对接研究中,获得的结合亲和力值5a–i表明COX-2(PDB ID:1CX2)对COX-1(PDB ID:1EQG)的治疗选择性。已确定的抑制常数(ki)值与纳摩尔/皮摩尔对COX-2的抑制常数一样低。可靠的COX-2抑制率为78–92%,IC500.002–1.28?获得μM。研究发现,高达98%的人红细胞膜被5a–i有效稳定/保护。优良的抗氧化性能(平均清除自由基92%)和构效关系预测证实了5a-i作为有效的未来抗炎药的潜在可药用性。细胞毒性

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号